Drug Patents owned by Sunovion

1. List of Xopenex Hfa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7256310 SUNOVION Levalbuterol salt
Oct, 2024

(1 year, 8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765153 SUNOVION Levalbuterol salt
Dec, 2023

(10 months from now)

Drugs and Companies using LEVALBUTEROL TARTRATE ingredient

Market Authorisation Date: 11 March, 2005

Treatment: Treatment or prevention of bronchospasm or asthmatic symptoms


How can I launch a generic of XOPENEX HFA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic